Description

CJC-1295 (No DAC) 5mg + Ipamorelin 5mg — Dual Pathway Research Peptide for GH Axis Studies

Comprehensive Scientific Overview

CJC-1295 (No DAC) and Ipamorelin represent a well-characterized dual-pathway peptide combination widely studied in growth hormone (GH) axis research. This synergistic pairing combines a growth hormone–releasing hormone (GHRH) analog with a selective ghrelin receptor (GHSR-1a) agonist, allowing researchers to investigate pulsatile GH dynamics, IGF-1 signaling, and pituitary responsiveness in controlled laboratory models.

CJC-1295 (No DAC) is a modified GHRH (1-29) analog designed to stimulate physiologic GH release through pituitary receptor activation, while Ipamorelin selectively activates ghrelin receptors with minimal impact on cortisol or prolactin pathways in preclinical studies.

At NeuroForge Peptides, this blend is supplied at ≥98% purity in lyophilized form and analytically verified via HPLC and mass spectrometry to support consistency and reliability in research environments. This material is intended strictly for in vitro and animal research and is not for human or veterinary use.

---

Mechanism of Action

The CJC-1295 (No DAC) + Ipamorelin combination operates through complementary endocrine pathways:

• GHRH receptor stimulation (CJC-1295 No DAC) — Promotes physiologic pulsatile GH release from the anterior pituitary (Teichman et al., 2006)
• Ghrelin receptor activation (Ipamorelin) — Selectively stimulates GHSR-1a to enhance GH pulse amplitude (Raun et al., 1998)
• Synergistic GH pulsatility — Dual signaling may amplify natural GH secretion patterns in research models
• Minimal off-target endocrine activity — Ipamorelin demonstrates low affinity for ACTH/cortisol pathways in preclinical data

---

Key Research Applications

1. Growth Hormone Axis Research

This combination is widely used to study pituitary GH dynamics and pulsatile secretion patterns.

Observed research endpoints

• Increased GH pulse amplitude

• Enhanced IGF-1 signaling pathways

• Improved pituitary responsiveness

Supporting literature

Teichman et al., 2006 — GHRH analog effects on GH secretion
Raun et al., 1998 — Ipamorelin selective GH release properties

---

2. IGF-1 and Anabolic Signaling Studies

The GH → IGF-1 axis remains central to metabolic and tissue research.

Common research focuses:

• Hepatic IGF-1 production

• Downstream mTOR signaling

• Protein synthesis pathways

• Tissue remodeling models

Preclinical findings suggest dual-pathway stimulation may produce more physiologic GH patterns compared with single-agent approaches.

---

3. Sleep and Circadian GH Research

Because endogenous GH secretion is tightly linked to sleep cycles, this blend is frequently studied in chronobiology models.

Research observations include:

• Nocturnal GH pulse amplification

• Interaction with slow-wave sleep phases

• Hypothalamic–pituitary timing dynamics

---

4. Body Composition and Metabolic Research

In animal models, GH axis modulation is studied for effects on:

• Adipose tissue metabolism

• Lean mass signaling pathways

• Lipolysis markers

• Glucose utilization

These applications make the combination valuable in metabolic and endocrine research settings.

---

Research Usage Guidelines

For laboratory research only. Not for human or veterinary use.

---

Product Specifications

• Peptides: CJC-1295 (No DAC) + Ipamorelin

• Quantity: 5 mg / 5 mg per vial

• Purity: ≥98%

• Form: Lyophilized powder in sterile glass vial

• Class: GHRH analog + GHSR agonist

• Storage: −20 °C recommended

---

Reconstitution & Handling

• Solvent: Sterile bacteriostatic water

• Lyophilized stability: 24 months at −20 °C

• Reconstituted stability: Up to 30 days at 4 °C

• Avoid repeated freeze–thaw cycles

• Protect from light

---

Why Choose NeuroForge Peptides

✔ ≥98% HPLC-verified purity
✔ Dual-pathway research blend
✔ Lyophilized for stability
✔ Third-party testing available
✔ Fast, discreet U.S. shipping

---

Important Notice

Research Use Only: This product is sold exclusively for laboratory research purposes. It is not approved for human or veterinary use. Purchasers are responsible for compliance with all applicable regulations governing research materials.

---

References

Teichman et al. — Effects of GHRH analogs on GH secretion
Raun et al. — Ipamorelin selective GH secretagogue properties
Bowers et al. — Growth hormone secretagogue receptor research
Smith et al. — Ghrelin receptor physiology